ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

A. Passaro; N. Leighl; F. Blackhall; S. Popat; K. Kerr; M. J. Ahn; M. E. Arcila; O. Arrieta; D. Planchard; F. de Marinis; A. M. Dingemans; R. Dziadziuszko; C. Faivre-Finn; J. Feldman; E. Felip; G. Curigliano; R. Herbst; P. A. Jänne; T. John; T. Mitsudomi; T. Mok; N. Normanno; L. Paz-Ares; S. Ramalingam; L. Sequist; J. Vansteenkiste; I. I. Wistuba; J. Wolf; Y. L. Wu; S. R. Yang; J. C.H. Yang; Y. Yatabe; G. Pentheroudakis; S. Peters

doi:10.1016/j.annonc.2022.02.003

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

A. Passaro, N. Leighl, F. Blackhall, S. Popat, K. Kerr, M. J. Ahn, M. E. Arcila, O. Arrieta, D. Planchard, F. de Marinis, A. M. Dingemans, R. Dziadziuszko, C. Faivre-Finn, J. Feldman, E. Felip, G. Curigliano, R. Herbst, P. A. Jänne, T. John, T. MitsudomiT. Mok, N. Normanno, L. Paz-Ares, S. Ramalingam, L. Sequist, J. Vansteenkiste, I. I. Wistuba, J. Wolf, Y. L. Wu, S. R. Yang, J. C.H. Yang, Y. Yatabe, G. Pentheroudakis, S. Peters

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

94 Citations (Scopus)

Résumé

The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer. The aim of the consensus was to develop recommendations on topics that are not covered in detail in the current ESMO Clinical Practice Guideline and where the available evidence is either limited or conflicting. The main topics identified for discussion were: (i) tissue and biomarkers analyses; (ii) early and locally advanced disease; (iii) metastatic disease and (iv) clinical trial design, patient's perspective and miscellaneous. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the recommendations developed, including findings from the expert panel discussions, consensus recommendations and a summary of evidence supporting each recommendation.

langue originale	Anglais
Pages (de - à)	466-487
Nombre de pages	22
journal	Annals of Oncology
Volume	33
Numéro de publication	5
Les DOIs	https://doi.org/10.1016/j.annonc.2022.02.003
état	Publié - 1 mai 2022

Accès au document

10.1016/j.annonc.2022.02.003

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Passaro, A., Leighl, N., Blackhall, F., Popat, S., Kerr, K., Ahn, M. J., Arcila, M. E., Arrieta, O., Planchard, D., de Marinis, F., Dingemans, A. M., Dziadziuszko, R., Faivre-Finn, C., Feldman, J., Felip, E., Curigliano, G., Herbst, R., Jänne, P. A., John, T., ... Peters, S. (2022). ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Annals of Oncology, 33(5), 466-487. https://doi.org/10.1016/j.annonc.2022.02.003

@article{6468fd1953924f44b774d783a979a384,

title = "ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer",

abstract = "The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer. The aim of the consensus was to develop recommendations on topics that are not covered in detail in the current ESMO Clinical Practice Guideline and where the available evidence is either limited or conflicting. The main topics identified for discussion were: (i) tissue and biomarkers analyses; (ii) early and locally advanced disease; (iii) metastatic disease and (iv) clinical trial design, patient's perspective and miscellaneous. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the recommendations developed, including findings from the expert panel discussions, consensus recommendations and a summary of evidence supporting each recommendation.",

keywords = "EGFR, consensus, lung cancer, targeted therapy, testing, treatment",

author = "A. Passaro and N. Leighl and F. Blackhall and S. Popat and K. Kerr and Ahn, {M. J.} and Arcila, {M. E.} and O. Arrieta and D. Planchard and {de Marinis}, F. and Dingemans, {A. M.} and R. Dziadziuszko and C. Faivre-Finn and J. Feldman and E. Felip and G. Curigliano and R. Herbst and J{\"a}nne, {P. A.} and T. John and T. Mitsudomi and T. Mok and N. Normanno and L. Paz-Ares and S. Ramalingam and L. Sequist and J. Vansteenkiste and Wistuba, {I. I.} and J. Wolf and Wu, {Y. L.} and Yang, {S. R.} and Yang, {J. C.H.} and Y. Yatabe and G. Pentheroudakis and S. Peters",

note = "Publisher Copyright: {\textcopyright} 2022 European Society for Medical Oncology",

year = "2022",

month = may,

day = "1",

doi = "10.1016/j.annonc.2022.02.003",

language = "English",

volume = "33",

pages = "466--487",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "5",

}

Passaro, A, Leighl, N, Blackhall, F, Popat, S, Kerr, K, Ahn, MJ, Arcila, ME, Arrieta, O, Planchard, D, de Marinis, F, Dingemans, AM, Dziadziuszko, R, Faivre-Finn, C, Feldman, J, Felip, E, Curigliano, G, Herbst, R, Jänne, PA, John, T, Mitsudomi, T, Mok, T, Normanno, N, Paz-Ares, L, Ramalingam, S, Sequist, L, Vansteenkiste, J, Wistuba, II, Wolf, J, Wu, YL, Yang, SR, Yang, JCH, Yatabe, Y, Pentheroudakis, G & Peters, S 2022, 'ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer', Annals of Oncology, VOL. 33, Numéro 5, p. 466-487. https://doi.org/10.1016/j.annonc.2022.02.003

TY - JOUR

T1 - ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

AU - Passaro, A.

AU - Leighl, N.

AU - Blackhall, F.

AU - Popat, S.

AU - Kerr, K.

AU - Ahn, M. J.

AU - Arcila, M. E.

AU - Arrieta, O.

AU - Planchard, D.

AU - de Marinis, F.

AU - Dingemans, A. M.

AU - Dziadziuszko, R.

AU - Faivre-Finn, C.

AU - Feldman, J.

AU - Felip, E.

AU - Curigliano, G.

AU - Herbst, R.

AU - Jänne, P. A.

AU - John, T.

AU - Mitsudomi, T.

AU - Mok, T.

AU - Normanno, N.

AU - Paz-Ares, L.

AU - Ramalingam, S.

AU - Sequist, L.

AU - Vansteenkiste, J.

AU - Wistuba, I. I.

AU - Wolf, J.

AU - Wu, Y. L.

AU - Yang, S. R.

AU - Yang, J. C.H.

AU - Yatabe, Y.

AU - Pentheroudakis, G.

AU - Peters, S.

PY - 2022/5/1

Y1 - 2022/5/1

N2 - The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer. The aim of the consensus was to develop recommendations on topics that are not covered in detail in the current ESMO Clinical Practice Guideline and where the available evidence is either limited or conflicting. The main topics identified for discussion were: (i) tissue and biomarkers analyses; (ii) early and locally advanced disease; (iii) metastatic disease and (iv) clinical trial design, patient's perspective and miscellaneous. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the recommendations developed, including findings from the expert panel discussions, consensus recommendations and a summary of evidence supporting each recommendation.

AB - The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer. The aim of the consensus was to develop recommendations on topics that are not covered in detail in the current ESMO Clinical Practice Guideline and where the available evidence is either limited or conflicting. The main topics identified for discussion were: (i) tissue and biomarkers analyses; (ii) early and locally advanced disease; (iii) metastatic disease and (iv) clinical trial design, patient's perspective and miscellaneous. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the recommendations developed, including findings from the expert panel discussions, consensus recommendations and a summary of evidence supporting each recommendation.

KW - EGFR

KW - consensus

KW - lung cancer

KW - targeted therapy

KW - testing

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85127265519&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2022.02.003

DO - 10.1016/j.annonc.2022.02.003

M3 - Article

C2 - 35176458

AN - SCOPUS:85127265519

SN - 0923-7534

VL - 33

SP - 466

EP - 487

JO - Annals of Oncology

JF - Annals of Oncology

IS - 5

ER -